Related Experiment Videos
Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib
1Department of Medicine, College of Medicine, University of Illinois at Chicago, USA.
The Journal of Rheumatology. Supplement
|October 14, 2000
Summary
Conventional nonsteroidal anti-inflammatory drugs (NSAID) carry risks of gastrointestinal (GI) complications. Selective cyclooxygenase-2 (COX-2) inhibitors like celecoxib offer a safer alternative for managing pain and inflammation.
Area of Science:
- Pharmacology
- Gastroenterology
- Rheumatology
Background:
- Conventional nonsteroidal anti-inflammatory drugs (NSAID) provide significant relief for musculoskeletal conditions but pose risks of gastrointestinal (GI) toxicity.
- Adverse GI effects range from mild dyspepsia to severe ulcer complications, limiting NSAID use.
- Understanding the roles of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes spurred the development of safer anti-inflammatory agents.
Purpose of the Study:
- To review the gastrointestinal risks associated with conventional NSAID.
- To compare the GI safety profile of conventional NSAID with the COX-2 specific inhibitor, celecoxib.
Main Methods:
- Literature review of NSAID-induced gastrointestinal complications.
- Comparative analysis of adverse event profiles between conventional NSAID and celecoxib.
Main Results:
- Conventional NSAID are linked to significant upper GI toxicities.
- Selective COX-2 inhibition aims to reduce GI risks while maintaining therapeutic efficacy.
Conclusions:
- Celecoxib represents a therapeutic advance with a potentially improved GI safety profile compared to conventional NSAID.
- Further research and clinical monitoring are essential for optimizing patient outcomes with NSAID and COX-2 inhibitors.